<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626717</url>
  </required_header>
  <id_info>
    <org_study_id>FR-03-CCL</org_study_id>
    <nct_id>NCT00626717</nct_id>
  </id_info>
  <brief_title>Riboflavin Mediated Corneal Crosslinking for Stabilizing Progression of Keratoconus</brief_title>
  <acronym>CCL</acronym>
  <official_title>Riboflavin Mediated Corneal Crosslinking for Stabilizing Progression of Keratoconus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peschke Meditrade, GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Corneal cross linking is a procedure that induces collagen cross linking of the
      corneal stroma due to release of reactive oxygen radicals upon activation of topically
      applied riboflavine A by UVA exposure. This procedure might be capable of reducing
      keratocouns progression.

      Purpose: Although there are no randomised controlled trials on the effectiveness of corneal
      cross linking for the treatment of keratoconus it gains more and more importance in the
      general clinical setting. Therefore, the investigators started such randomised, placebo
      controlled, double blinded, multicenter trial to find out if this treatment is as effective
      as it promises to be.

      Methods: Randomised, placebo controlled, double blinded, multicenter trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Keratoconus progression</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial cell loss</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Riboflavin/UVA crosslinking</intervention_name>
    <description>Removal of epithelium. Riboflavin eye drops. UVA exposure.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham treatment</intervention_name>
    <description>Fluorescein eye drops. Exposure with blue light</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Only early Keratoconus (Contact lens fitting)

          -  Progression of Ametropia.

          -  Corneal thickness &gt; 450µm

        Exclusion Criteria:

          -  Further ophthalmic diseases

          -  History of ocular surgery

          -  Pregnancy, brest feeding

          -  Allergy against Riboflavin

          -  End stage Keratoconus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Maier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Eye Hospital, Freiburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Eye Hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2008</study_first_submitted>
  <study_first_submitted_qc>February 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <last_update_submitted>January 16, 2013</last_update_submitted>
  <last_update_submitted_qc>January 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Freiburg</investigator_affiliation>
    <investigator_full_name>D Dr. Philip Maier</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Keratoconus</keyword>
  <keyword>Cross linking</keyword>
  <keyword>Riboflavin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

